Literature DB >> 25873094

Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era.

Florence K Keane1, Yui-Hui Chen2, Bridget A Neville3, Roy B Tishler4, Jonathan D Schoenfeld4, Paul J Catalano2, Danielle N Margalit4.   

Abstract

BACKGROUND: Although human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) tends to present at an advanced nodal stage (N stage), the prognosis is generally better than that for HPV-negative OPSCC. Prior work has demonstrated the increasing incidence of HPV-related OPSCC in the United States. This study was designed to determine whether the changing epidemiology of OPSCC is reflected in changes in the prognostic significance of the tumor stage (T stage) and the N stage in a population-based cohort.
METHODS: The Surveillance, Epidemiology, and End Results program was used to identify 13,328 patients who were 18 years old or older and were diagnosed with OPSCC from 1997 to 2008. The Kaplan-Meier method was used to estimate head and neck cancer-specific survival. Cox proportional hazards models were used to evaluate the associations between head and neck cancer-specific mortality (HNCSM) and T and N stages and the interaction of variables with the year of diagnosis.
RESULTS: With a median follow-up of 67 months, there were 4099 head and neck cancer deaths. There was a significant interaction between the T stage and time (P for interaction = .01), with the effect of the T stage on HNCSM increasing from 1997 to 2008. The T stage retained a linear relationship with HNCSM. The effect of the N stage on HNCSM declined over time (P for interaction = .0004). The current American Joint Committee on Cancer (AJCC) staging system did not subdivide distinct prognostic subgroups for HNCSM by overall stage.
CONCLUSIONS: In this population-based study of OPSCC, the effect of the N stage on cancer-specific mortality decreased over time as the impact of the T stage increased. The current AJCC staging system did not distinguish prognostic subgroups. These changes may reflect the increasing prevalence of HPV-related OPSCC. Further study in HPV-defined cohorts is needed to tailor the AJCC staging system to better reflect HNCSM risk. Cancer 2015;121:2594-2602.
© 2015 American Cancer Society. © 2015 American Cancer Society.

Entities:  

Keywords:  American Joint Committee on Cancer (AJCC) cancer staging; carcinoma; head and neck cancer; human papilloma virus; oropharyngeal cancer; squamous cell

Mesh:

Year:  2015        PMID: 25873094     DOI: 10.1002/cncr.29402

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Validation and assessment of discordance of the 8th edition AJCC (American Joint Committee on Cancer) clinical and pathologic staging systems in patients with p16+ oropharyngeal cancer treated with surgery and adjuvant radiation at a single institution.

Authors:  Piyush Gupta; Jocelyn C Migliacci; Ashley Hay; Matthew Rosenthal; Ximena Mimica; Nancy Lee; Richard J Wong; Jatin Shah; Snehal Patel; Ian Ganly
Journal:  Oral Oncol       Date:  2018-06-23       Impact factor: 5.337

2.  Prognostic value of the lymph node ratio in oropharyngeal carcinoma stratified for HPV-status.

Authors:  Christian Jacobi; Josepha Rauch; Jan Hagemann; Thomas Lautz; Maximilian Reiter; Philipp Baumeister
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-04       Impact factor: 2.503

3.  Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan.

Authors:  Takatsugu Mizumachi; Akihiro Homma; Tomohiro Sakashita; Satoshi Kano; Hiromitsu Hatakeyama; Satoshi Fukuda
Journal:  Int J Clin Oncol       Date:  2017-03-07       Impact factor: 3.402

4.  Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories.

Authors:  Kristina R Dahlstrom; Adam S Garden; William N William; Ming Yann Lim; Erich M Sturgis
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

5.  Comparison of Polymerase Chain Reaction and Immunohistochemistry Assays for Analysing Human Papillomavirus Infection in Oral Squamous Cell Carcinoma.

Authors:  Muhammad Sohail Awan; Babar Irfan; Ibrahim Zahid; Yumna Mirza; Syed Adnan Ali
Journal:  J Clin Diagn Res       Date:  2017-06-01

6.  Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma.

Authors:  Theresa Guo; Eleni Rettig; Carole Fakhry
Journal:  Oral Oncol       Date:  2015-11-14       Impact factor: 5.337

7.  Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx.

Authors:  B H Haughey; P Sinha; D Kallogjeri; R L Goldberg; J S Lewis; J F Piccirillo; R S Jackson; E J Moore; M Brandwein-Gensler; S J Magnuson; W R Carroll; T M Jones; M D Wilkie; A Lau; N S Upile; Jon Sheard; J Lancaster; S Tandon; M Robinson; D Husband; I Ganly; J P Shah; D M Brizel; B O'Sullivan; J A Ridge; W M Lydiatt
Journal:  Oral Oncol       Date:  2016-09-23       Impact factor: 5.337

8.  Disparities and guideline adherence for HPV testing among patients with oropharyngeal squamous cell carcinoma, NCDB, and SEER.

Authors:  Solomon Husain; Shivangi Lohia; Valentina Petkov; Timothy Blackwell; Samuel Swisher-McClure; Aviram Mizrachi; Luc G Morris; Marc A Cohen; Richard J Wong; Benjamin R Roman
Journal:  Head Neck       Date:  2021-04-13       Impact factor: 3.821

9.  Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer.

Authors:  Steffen Wagner; Claus Wittekindt; Shachi Jenny Sharma; Nora Wuerdemann; Theresa Jüttner; Miriam Reuschenbach; Elena-Sophie Prigge; Magnus von Knebel Doeberitz; Stefan Gattenlöhner; Ernst Burkhardt; Jörn Pons-Kühnemann; Jens Peter Klussmann
Journal:  Br J Cancer       Date:  2017-05-04       Impact factor: 7.640

Review 10.  Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy.

Authors:  Ashley Hay; Ian Ganly
Journal:  Rare Cancers Ther       Date:  2015-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.